Brazil's Breastfeeding Gap Filled by Biotech Startup's $5.9M Breakthrough

Brazil's Breastfeeding Legislation and the Rise of Domestic Innovation

Since the 1980s, Brazil has experienced a significant shift in family dynamics, with the number of families headed by women nearly doubling. This change has led to an unprecedented movement in breastfeeding legislation, aimed at supporting mothers in their roles as caregivers and employees.

As more women entered the workforce, they often found themselves juggling the triple responsibilities of being a mother, housewife, and employee. Research published in the Pediatric, Gastroenterology, Hepatology & Nutrition journal highlights how this transition frequently resulted in the interruption of breastfeeding. In response, Brazilian legislation introduced measures such as postpartum leave of up to four months and two half-hour intervals during working hours—allowing new parents to breastfeed their babies. Companies were also encouraged to extend maternity leave to six months through tax incentives, while the Ministry of Health launched the “Supporting Working Women and Breastfeeding” program in 2010.

Despite these efforts, the benefits of such legislation are limited to those employed under formal contracts. While 52.5% of women participate in the labor force, only 37.9% are formally employed, leaving approximately 132.273 million women without protection. This gap underscores the challenges faced by informal workers, who often lack access to essential support systems.

The Brazilian market is heavily influenced by multinational corporations, which have long dominated the industry. Giants like Nestlé and Danone collectively control 90% of the market, while other companies continue to expand their presence in the region. These corporations have invested significantly in lobbying efforts, shaping policies that favor their operations.

The influence of these multinationals has had far-reaching consequences. According to a study by the European Public Health Alliance (EPHA), their practices are altering traditional diets and contributing to widespread obesity and health issues in Brazil. Many products remain unnecessarily sugary, with additives that can be harmful to infants' developing metabolic systems.

In addition to these challenges, one in six infants are allergic to cow’s milk, traditionally used as the base for infant formula. This creates a difficult dilemma for Brazilian parents: choosing between international corporation products that pose risks or maintaining a breastmilk-exclusive diet while navigating a demanding workforce.

A New Era of Innovation

MIT-based biotechnology company Harmony Baby Nutrition recognized this growing need early on. Founded in 2018 by Wendel Afonso, a native from Minas Gerais, the startup developed the first human breastmilk-based infant formula available in the market. Their first product, Melodi, is a specialized toddler formula that uses lactose as its carbohydrate source, includes the sugars found in breast milk, and contains vitamins, minerals, nucleotides, an oil blend, and fatty acids that replicate the composition of human milk.

Afonso and his team have recently secured $5.9 million USD in funding from the FINEP-BNDES innovation fund to establish a new research and development (R&D) center in Belo Horizonte, Minas Gerais. This initiative aims to create a world-class research and production ecosystem, positioning Brazil as a global leader in humanized infant formula innovation.

“There is currently no domestic infant formula industry in Brazil; the market has been dominated for decades by large multinational companies,” said Afonso, who is also CEO at Harmony. “This funding allows us to establish a world-class research and production ecosystem right here in Belo Horizonte. In doing so, we are also positioning Brazil as a global leader in humanized infant formula innovation.”

The Role of FINEP-BNDES

FINEP-BNDES is one of Brazil’s foremost innovation funds, established under the Nova Indústria Brasil policy introduced in January 2024. This policy aims to stimulate productive technological development, guide investment, and expand the country’s industrial competitiveness. Since its launch, the policy has allocated $555 million USD to strengthen domestic innovation capacity and select companies capable of large-scale R&D infrastructure.

The selection of Harmony is not only a testament to Brazil reversing its premature deindustrialization but also to the startup’s scientific leadership and global potential.

Expanding Capabilities

The project will recruit 25 professionals, including at least five scientists with masters’ or doctoral degrees. These experts will contribute across multidisciplinary domains, including scientific, technical, administrative, and operational capacities.

The new center, spanning 250 square meters, will feature advanced laboratories dedicated to R&D, quality control, and a state-of-the-art application plant with high-precision and efficient technologies. Its goal is to develop and improve formulations tailored to diverse clinical and nutritional needs, as well as investigate the bioactive properties of breastmilk.